Abzena, an integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on developing fully human antibodies, formed a strategic partnership.  This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development services.
 To help address the challenges of early-stage development, Mabqi and Abzena aim to enable d...